RapidAI Receives FDA Clearance for Rapid Hyperdensity Device

The FDA has granted RapidAI 510(k) marketing clearance for its Rapid Hyperdensity device for assessing the severity of injury in patients with acute neurological conditions such as traumatic brain injury and brain hemorrhages.

The device uses computed tomography scans and artificial intelligence to assess the volume of hyperdense tissue in the brain and identify the extent of a hemorrhage.

The Rapid Hyperdensity device can provide contextual data that enables physicians to make more informed decisions. It delivers results that can be accessed in several ways, including email or a mobile app.